Launch Report: Pharmatech

Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.

Introducing pharmatech VC and PE research 

We’re launching new coverage of the pharmatech sector, an industry comprising contract organizations and outsourcing services for drug research, development, and manufacturing—CROs, CDMOs, and CMOs for those in the know. Kazi Helal, Ph.D., PitchBook's Senior Analyst covering biotech, breaks out the market landscape and deal activity across segments in the inaugural report. 

Takeaways include: 
 

• The sector has traditionally been dominated by a handful of large companies. However, both PE and VC investors are now finding inroads and leveraging the current turbulence of post-pandemic global biomanufacturing needs to syndicate deals in this emerging lucrative space. 

 

• As with the broader biopharma industry, deal activity has moderated from post-pandemic peaks and showed continued pressure in early 2024. PE investors have focused on consolidation of mature companies, while VC firms have launched the future of pharmatech.  

 

• Investors are finding opportunity in novel technologies like AI & ML for drug discovery and clinical trials, as well as maturing ones like cell & gene therapies, where high demand creates need for scalable manufacturing.